旭輝控股集團(00884.HK)完成先舊後新配售3.05億股 淨籌6.23億港元
格隆匯9月5日丨旭輝控股集團(00884.HK)宣佈,配售事項及認購事項完成已分別於2022年9月2日及2022年9月5日落實。合共3.05億股配售股份已成功按配售價每股2.06港元配售予不少於6名獲配售人。
此外,認購事項全部條件已達成且認購事項已於2022年9月5日完成。賣方已按認購價(與配售價相同)認購合共3.05億股認購股份(相當於根據配售事項成功配售的配售股份數目)。認購股份相當於認購事項完成後經擴大的已發行股份總數約3.23%。
公司自認購事項收取的所得款項淨額約為6.23億港元,並擬將認購事項所得款項淨額用於現有債務再融資及用作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.